Yuanbin Chen

Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer

Ying Cheng, David R. Spigel, Byoung Chul Cho et al. · New England Journal of Medicine · 2024 · 275 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

LBA6 Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801)

S. Patel, Megan Othus, Víctor M. Prieto et al. · Annals of Oncology · 2022 · 56 citations · Full text

Medicine, Oncology, Immunotherapy +15

Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden

Luis Paz‐Ares, Marina Chiara Garassino, Yuanbin Chen et al. · Clinical Cancer Research · 2023 · 54 citations · Full text

Medicine, Oncology, Pharmacology +17

PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN

Luis Paz‐Ares, Jonathan W. Goldman, Marina Chiara Garassino et al. · Annals of Oncology · 2019 · 52 citations · Full text

Medicine, Oncology, Pharmacology +10

ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC).

David R. Spigel, Ying Cheng, Byoung Chul Cho et al. · Journal of Clinical Oncology · 2024 · 46 citations

Medicine, Oncology, Pharmacotherapy +16